Physician profile
Alan Bryson
NPI 1740675487
$2,639.83
in general payments reported to CMS, 2019-2025
27 companies · $281 in 2025
The $281 reported for 2025 was more than what a typical Medical provider received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $786 · 2022: $530 · 2023: $590 · 2024: $454 · 2025: $281.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,324.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,323.72 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $435.84 | 2021-2025 | |
| Lilly USA, LLC | $360.11 | 2021-2025 | Jardiance, Mounjaro, Zepbound |
| Amgen INC. | $338.73 | 2021-2024 | Evenity, Prolia, Repatha |
| Novo Nordisk INC | $294.64 | 2021-2025 | Ozempic, Rybelsus |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $157.60 | 2021-2022 | |
| Abbott Laboratories | $135.41 | 2021-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $100.21 | 2023-2025 | |
| Vanda Pharmaceuticals INC. | $96.76 | 2021-2023 | Hetlioz |
| Averitas Pharma INC. | $95.20 | 2023-2025 | Qutenza |
| Janssen Pharmaceuticals, INC | $69.41 | 2022-2025 | Xarelto, Spravato |
| Daiichi Sankyo INC. | $66.39 | 2021 | |
| Novartis Pharmaceuticals Corporation | $58.76 | 2022-2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $54.17 | 2021 | |
| Ibsa Pharma INC. | $50.21 | 2022-2023 | Tirosint, Licart |
| Merck Sharp & Dohme LLC | $49.61 | 2021-2022 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $39.90 | 2021-2025 | Farxiga |
| Astellas Pharma US INC | $38.22 | 2021 | |
| Shield Therapeutics INC | $35.90 | 2023 | Accrufer |
| Glaxosmithkline, LLC. | $34.51 | 2021-2023 | Arexvy, Shingrix, Trelegy Ellipta |
| Biohaven Pharmaceutical Holding Company LTD. | $19.66 | 2022 | |
| Xeris Pharmaceuticals, INC. | $18.85 | 2023 | Gvoke Hypopen |
| Dexcom, INC. | $18.19 | 2021 | |
| Exact Sciences Corporation | $17.57 | 2024 | Cologuard Collection Kit |
| Boehringer Ingelheim Pharmaceuticals, INC. | $15.85 | 2024 | |
| Pfizer INC. | $13.86 | 2023 | |
| E.R. Squibb & Sons, L.L.C. | $13.19 | 2022 | |
| Adlon Therapeutics L.P. | $11.08 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alan Bryson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.